Search results (1331)
« Back to PublicationsRE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR
O'Byrne S. et al, (2017), HAEMATOLOGICA, 102, 80 - 80
Erratum to: Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2017), Target Oncol, 12
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
Giustacchini A. et al, (2017), Nat Med, 23, 692 - 702
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.
Corrie P. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Chen RW. et al, (2017), JOURNAL OF CLINICAL ONCOLOGY, 35
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA. et al, (2017), Lancet Haematol, 4, e225 - e236
Pre-metastatic niches: organ-specific homes for metastases.
Peinado H. et al, (2017), Nature reviews. Cancer, 17, 302 - 317
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A. et al, (2017), Blood, 129, 2224 - 2232
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
Lahr RM. et al, (2017), eLife, 6
A practical application of time to event analysis in the presence of non-proportional hazards
Mohammed SB. et al, (2017)
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
Eyre TA. et al, (2017), British journal of haematology
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
Findlay JM. et al, (2017), Br J Surg, 104, 408 - 417
The RNA-binding protein LARP1 is a cancer therapeutic target
Ghazaly EA. et al, (2017), CANCER RESEARCH, 77
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
Hall PS. et al, (2017), British journal of cancer, 116, 472 - 478
Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
Long GV. et al, (2017), EUROPEAN JOURNAL OF CANCER, 72, S128 - S129
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A. et al, (2017), PLoS Med, 14, e1002230 - e1002230
Equivalence of BCSH and WHO diagnostic criteria for ET.
Harrison CN. et al, (2017), Leukemia, 31, 527 - 528